GNLX: Genelux Corporation Stock

by  •  • Comments Off on GNLX: Genelux Corporation Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 87.30
Enterprise Value ($M) 81.20
Book Value ($M) 33.09
Book Value / Share 0.97
Price / Book 2.64
NCAV ($M) 28.79
NCAV / Share 0.84
Price / NCAV 3.03

Profitability (mra)
Return on Invested Capital (ROIC) -0.79
Return on Assets (ROA) -0.81
Return on Equity (ROE) -1.15

Liquidity (mrq)
Quick Ratio 6.47
Current Ratio 6.47

Balance Sheet (mrq) ($M)
Current Assets 35.97
Assets 40.27
Liabilities 7.18
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
10-25 13G Highbridge Capital Management Llc 6.80
10-22 13G/A Szalay Aladar 9.90 -18.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-26 49,119 98,238 50.00
2024-11-25 64,936 244,087 26.60
2024-11-22 59,746 190,378 31.38
2024-11-21 48,721 159,799 30.49

(click for more detail)

Similar Companies
GLMD – Galmed Pharmaceuticals Ltd. GLSI – Greenwich LifeSciences, Inc.
GLTO – Galecto, Inc. GNPX – Genprex, Inc.
GOVX – GeoVax Labs, Inc.


Financial data and stock pages provided by
Fintel.io